Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Adrian Sacher

Showing results (41-50 of 56) with videos related to

Pageof 6
Sort By:
Therapeutic Advances in Medical Oncology|September 26, 2022
Plasma-first: accelerating lung cancer diagnosis and molecular profiling through liquid biopsyMiguel Garcia-Pardo, Kasia Czarnecka, Jennifer H Law, et al.
Lung Cancer (Amsterdam, Netherlands)|January 9, 2025
Assessing the feasibility and external validity of natural language processing-extracted data for advanced lung cancer patientsYuchen Li, Jennifer Law, Lisa W Le, et al.
The New England Journal of Medicine|June 7, 2021
Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C MutationFerdinandos Skoulidis, Bob T Li, Grace K Dy, et al.
Cancer|January 9, 2020
Development of the Functional Assessment of Cancer Therapy-Immune Checkpoint Modulator (FACT-ICM): A toxicity subscale to measure quality of life in patients with cancer who are treated with ICMsAaron R Hansen, Kari Ala-Leppilampi, Chris McKillop, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 30, 2025
Efficacy and Safety of Olomorasib in Combination With Pembrolizumab in Treatment of Patients With KRAS G12C-Mutant Advanced NSCLCTimothy F Burns, Natraj Reddy Ammakkanavar, Antoine Hollebecque, et al.
European Journal of Cancer (Oxford, England : 1990)|November 26, 2020
Durvalumab therapy following chemoradiation compared with a historical cohort treated with chemoradiation alone in patients with stage III non-small cell lung cancer: A real-world multicentre studyAntoine Desilets, Félix Blanc-Durand, Sally Lau, et al.
Cancer Discovery|April 7, 2024
CD70-Targeted Allogeneic CAR T-Cell Therapy for Advanced Clear Cell Renal Cell CarcinomaSumanta K Pal, Ben Tran, John B A G Haanen, et al.
Nature Communications|March 13, 2026
Pan-tumor activity of olomorasib, a next-generation KRAS G12C inhibitor in KRAS G12C-mutant advanced solid tumors: a first-in-human studyYonina R Murciano-Goroff, Antoine Hollebecque, Rebecca S Heist, et al.
The New England Journal of Medicine|August 23, 2023
Single-Agent Divarasib (GDC-6036) in Solid Tumors with a <i>KRAS</i> G12C MutationAdrian Sacher, Patricia LoRusso, Manish R Patel, et al.
Nature Medicine|May 28, 2025
Molecular determinants of sotorasib clinical efficacy in KRAS<sup>G12C</sup>-mutated non-small-cell lung cancerFerdinandos Skoulidis, Bob T Li, Adrianus Johannes de Langen, et al.
Pageof 6

Showing results (41-50 of 56) with videos related to

Sort By:
Pageof 6
Therapeutic Advances in Medical Oncology|September 26, 2022
Plasma-first: accelerating lung cancer diagnosis and molecular profiling through liquid biopsyMiguel Garcia-Pardo, Kasia Czarnecka, Jennifer H Law, et al.
Lung Cancer (Amsterdam, Netherlands)|January 9, 2025
Assessing the feasibility and external validity of natural language processing-extracted data for advanced lung cancer patientsYuchen Li, Jennifer Law, Lisa W Le, et al.
The New England Journal of Medicine|June 7, 2021
Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C MutationFerdinandos Skoulidis, Bob T Li, Grace K Dy, et al.
Cancer|January 9, 2020
Development of the Functional Assessment of Cancer Therapy-Immune Checkpoint Modulator (FACT-ICM): A toxicity subscale to measure quality of life in patients with cancer who are treated with ICMsAaron R Hansen, Kari Ala-Leppilampi, Chris McKillop, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 30, 2025
Efficacy and Safety of Olomorasib in Combination With Pembrolizumab in Treatment of Patients With KRAS G12C-Mutant Advanced NSCLCTimothy F Burns, Natraj Reddy Ammakkanavar, Antoine Hollebecque, et al.
European Journal of Cancer (Oxford, England : 1990)|November 26, 2020
Durvalumab therapy following chemoradiation compared with a historical cohort treated with chemoradiation alone in patients with stage III non-small cell lung cancer: A real-world multicentre studyAntoine Desilets, Félix Blanc-Durand, Sally Lau, et al.
Cancer Discovery|April 7, 2024
CD70-Targeted Allogeneic CAR T-Cell Therapy for Advanced Clear Cell Renal Cell CarcinomaSumanta K Pal, Ben Tran, John B A G Haanen, et al.
Nature Communications|March 13, 2026
Pan-tumor activity of olomorasib, a next-generation KRAS G12C inhibitor in KRAS G12C-mutant advanced solid tumors: a first-in-human studyYonina R Murciano-Goroff, Antoine Hollebecque, Rebecca S Heist, et al.
The New England Journal of Medicine|August 23, 2023
Single-Agent Divarasib (GDC-6036) in Solid Tumors with a <i>KRAS</i> G12C MutationAdrian Sacher, Patricia LoRusso, Manish R Patel, et al.
Nature Medicine|May 28, 2025
Molecular determinants of sotorasib clinical efficacy in KRAS<sup>G12C</sup>-mutated non-small-cell lung cancerFerdinandos Skoulidis, Bob T Li, Adrianus Johannes de Langen, et al.
Pageof 6